Results 81 to 90 of about 25,335 (131)
Musculoskeletal Care, Volume 23, Issue 2, June 2025.ABSTRACT Objective Lack of insurance coverage, limited access to health services and lower socioeconomic status (SES) are contributors to inadequate utilization of biologic disease modifying anti‐rheumatic drugs (bDMARD) in rheumatoid arthritis (RA). The broad national insurance coverage for bDMARDs in Israel provides a unique opportunity to study the ...
Fadi Hassan +6 more
wiley +1 more source
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent [PDF]
, 2013 Aims: The aim of this study is to assess concordance with the British Society of Rheumatology (BSR) 2010 recommendations on the use of biologic therapy in Rheumatoid Arthritis (RA).
Borg, Andrew A. +2 more
core
Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.ABSTRACT Our study aimed to examine medication adherence (MA) to tadalafil 5 mg once daily (OaD) in patients undergoing treatment for erectile dysfunction (ED) and to identify factors contributing to potential drug noncompliance. This cross‐sectional study included 233 patients diagnosed with ED. Sociodemographic and clinical data were recorded. MA was
Emre Kandemir, Onur Kucuktopcu
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 91, Issue 6, Page 1586-1599, June 2025.Aims The COVID‐19 pandemic created unprecedented pressure on healthcare services. This study investigates whether disease‐modifying antirheumatic drug (DMARD) safety monitoring was affected during the COVID‐19 pandemic. Methods A population‐based cohort study was conducted using the OpenSAFELY platform to access electronic health record data from 24.2 ...
Andrew D. Brown +27 more
wiley +1 more source
Social media as a source of drug safety information in the paediatric population
British Journal of Clinical Pharmacology, Volume 91, Issue 6, Page 1760-1770, June 2025.Aims The paediatric population is vulnerable to suffering adverse drug events (ADEs) such as negative outcomes due to medication (NOMs)–drug related problems (DRPs), especially adverse drug reactions (ADRs) and medication errors (MEs). Social media (SM) is considered an interesting tool for pharmacovigilance.
Ingrid Vilimelis‐Piulats +5 more
wiley +1 more source
Rheumatoid arthritis and spondyloarthropathy [PDF]
, 2013 Part 2 of the article can be found through this link: https://www.um.edu.mt/library/oar//handle/123456789/13280Rheumatoid arthritis (RA) and spondyloarthropathy are two groups of inflammatory joint disease.
Vassallo, Pierre
core
Recent Therapeutics Policies of Arthritis Rheumatoid (Part I) [PDF]
, 2018 Therapy in RA has undergone many advances today and in line with knowledge of the pathogenesis of RA, the current therapeutic goal is to alter the journey and control the activity of RA disease.
Andisari, H. E. (Hendrata)
core
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition [PDF]
, 2006 BACKGROUND:Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation.
Adams, BS +39 more
core
Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]
, 2006 A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core